A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

Key Inclusion Criteria: * Adults age \> or equal to18 at the time the Informed Consent is signed * Refractory or relapsed pathologically confirmed T Cell Lymphoma (TCL): Peripheral T cell Lymphoma not otherwise specified (PTCL-NOS) , Angioimmunoblastic T cell Lymphoma (AITL), ALK-negative anaplastic large cell lymphoma (ALCL), ALK-positive ALCL, or Mycosis Fungoides (MF) stage IIB-IV including large cell transformation * CD5-expressing tumor by IHC or flow cytometry of tumor biopsy within 3 months of Screening or at Screening * Eastern Cooperative Oncology Group performance status \< 2 * Adequate organ function as defined in the protocol. Key Exclusion Criteria: * B1 and B2 disease (as defined in protocol for subjects with MF) * Known central nervous system involvement by PTCL * History of allogeneic transplant * History of intolerance to leukapheresis, plasmapheresis, or blood donation * Pregnant or nursing women * Any acute illness including fever (\> 100.4°F or \> 38°C), except fever related to tumor * Active systemic bacterial, fungal, or viral infection * Active chronic infection * Other primary malignancies, except adequately treated malignancies or complete remission * Active autoimmune disease that has required systemic therapy in the last 2 years * History of hemophagocytic lymphohistiocytosis * History of severe, immediate hypersensitivity reaction attributed to penicillin * Any other condition that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the study requirements.